JP2006516086A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006516086A5 JP2006516086A5 JP2004525545A JP2004525545A JP2006516086A5 JP 2006516086 A5 JP2006516086 A5 JP 2006516086A5 JP 2004525545 A JP2004525545 A JP 2004525545A JP 2004525545 A JP2004525545 A JP 2004525545A JP 2006516086 A5 JP2006516086 A5 JP 2006516086A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- fragment
- mab
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims 47
- 125000003275 alpha amino acid group Chemical group 0.000 claims 16
- 238000001514 detection method Methods 0.000 claims 13
- 102000013529 alpha-Fetoproteins Human genes 0.000 claims 12
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 12
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 10
- 229940124597 therapeutic agent Drugs 0.000 claims 8
- 108020001507 fusion proteins Proteins 0.000 claims 7
- 102000037865 fusion proteins Human genes 0.000 claims 7
- 230000001225 therapeutic effect Effects 0.000 claims 7
- 239000000427 antigen Substances 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 150000001413 amino acids Chemical class 0.000 claims 5
- 238000003745 diagnosis Methods 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 102100032528 C-type lectin domain family 11 member A Human genes 0.000 claims 2
- 101710167766 C-type lectin domain family 11 member A Proteins 0.000 claims 2
- 102000007644 Colony-Stimulating Factors Human genes 0.000 claims 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 108700020796 Oncogene Proteins 0.000 claims 2
- 102100035194 Placenta growth factor Human genes 0.000 claims 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims 2
- 239000002955 immunomodulating agent Substances 0.000 claims 2
- 229940121354 immunomodulator Drugs 0.000 claims 2
- 230000002584 immunomodulator Effects 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- 239000003053 toxin Substances 0.000 claims 2
- 231100000765 toxin Toxicity 0.000 claims 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims 1
- 102000003951 Erythropoietin Human genes 0.000 claims 1
- 108090000394 Erythropoietin Proteins 0.000 claims 1
- 108050000784 Ferritin Proteins 0.000 claims 1
- 102000008857 Ferritin Human genes 0.000 claims 1
- 238000008416 Ferritin Methods 0.000 claims 1
- 102100037362 Fibronectin Human genes 0.000 claims 1
- 108010067306 Fibronectins Proteins 0.000 claims 1
- 229910052688 Gadolinium Inorganic materials 0.000 claims 1
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 claims 1
- 101000623904 Homo sapiens Mucin-17 Proteins 0.000 claims 1
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 102000004889 Interleukin-6 Human genes 0.000 claims 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 claims 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 102100034256 Mucin-1 Human genes 0.000 claims 1
- 108010008707 Mucin-1 Proteins 0.000 claims 1
- 102100023125 Mucin-17 Human genes 0.000 claims 1
- 102100034263 Mucin-2 Human genes 0.000 claims 1
- 108010008705 Mucin-2 Proteins 0.000 claims 1
- 102100022693 Mucin-4 Human genes 0.000 claims 1
- 108010008699 Mucin-4 Proteins 0.000 claims 1
- 101100370002 Mus musculus Tnfsf14 gene Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 102000043276 Oncogene Human genes 0.000 claims 1
- 108010082093 Placenta Growth Factor Proteins 0.000 claims 1
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 108010083644 Ribonucleases Proteins 0.000 claims 1
- 102000006382 Ribonucleases Human genes 0.000 claims 1
- 108010008125 Tenascin Proteins 0.000 claims 1
- 102000007000 Tenascin Human genes 0.000 claims 1
- 102000036693 Thrombopoietin Human genes 0.000 claims 1
- 108010041111 Thrombopoietin Proteins 0.000 claims 1
- 102100027212 Tumor-associated calcium signal transducer 2 Human genes 0.000 claims 1
- 206010054094 Tumour necrosis Diseases 0.000 claims 1
- 150000001224 Uranium Chemical group 0.000 claims 1
- 229910052770 Uranium Inorganic materials 0.000 claims 1
- 108010021355 acidic isoferritin Proteins 0.000 claims 1
- 229930013930 alkaloid Natural products 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 230000002491 angiogenic effect Effects 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 239000003080 antimitotic agent Substances 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 229910052796 boron Inorganic materials 0.000 claims 1
- 101150061829 bre-3 gene Proteins 0.000 claims 1
- 125000000837 carbohydrate group Chemical group 0.000 claims 1
- 229940111134 coxibs Drugs 0.000 claims 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 1
- 239000002532 enzyme inhibitor Substances 0.000 claims 1
- 229940125532 enzyme inhibitor Drugs 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 229940105423 erythropoietin Drugs 0.000 claims 1
- GMBVGUFXJFKNMR-UHFFFAOYSA-N gadolinium Chemical compound [Gd].[Gd].[Gd] GMBVGUFXJFKNMR-UHFFFAOYSA-N 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 230000003394 haemopoietic effect Effects 0.000 claims 1
- -1 hematopoietic factor Proteins 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 239000003667 hormone antagonist Substances 0.000 claims 1
- QCQYVCMYGCHVMR-AAZUGDAUSA-N n-[(2r,3r,4s,5r)-4,5,6-trihydroxy-1-oxo-3-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexan-2-yl]acetamide Chemical compound CC(=O)N[C@@H](C=O)[C@H]([C@@H](O)[C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O QCQYVCMYGCHVMR-AAZUGDAUSA-N 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 1
- 108010061338 ranpirnase Proteins 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 101150047061 tag-72 gene Proteins 0.000 claims 1
- 230000006444 vascular growth Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39970702P | 2002-08-01 | 2002-08-01 | |
| US60/399,707 | 2002-08-01 | ||
| PCT/GB2003/003325 WO2004013180A2 (en) | 2002-08-01 | 2003-08-01 | Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010073011A Division JP5161254B2 (ja) | 2002-08-01 | 2010-03-26 | α−フェトタンパク質Ｉｍｍｕ３１抗体および融合タンパク質ならびにその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006516086A JP2006516086A (ja) | 2006-06-22 |
| JP2006516086A5 true JP2006516086A5 (enExample) | 2006-08-03 |
| JP5138867B2 JP5138867B2 (ja) | 2013-02-06 |
Family
ID=31495756
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004525545A Expired - Fee Related JP5138867B2 (ja) | 2002-08-01 | 2003-08-01 | α−フェトタンパク質Ｉｍｍｕ３１抗体および融合タンパク質ならびにその使用方法 |
| JP2010073011A Expired - Fee Related JP5161254B2 (ja) | 2002-08-01 | 2010-03-26 | α−フェトタンパク質Ｉｍｍｕ３１抗体および融合タンパク質ならびにその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010073011A Expired - Fee Related JP5161254B2 (ja) | 2002-08-01 | 2010-03-26 | α−フェトタンパク質Ｉｍｍｕ３１抗体および融合タンパク質ならびにその使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US7300655B2 (enExample) |
| EP (1) | EP1546203B1 (enExample) |
| JP (2) | JP5138867B2 (enExample) |
| KR (1) | KR101115797B1 (enExample) |
| AU (2) | AU2003248982B2 (enExample) |
| CA (1) | CA2494310A1 (enExample) |
| IL (1) | IL166632A (enExample) |
| WO (1) | WO2004013180A2 (enExample) |
Families Citing this family (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7569342B2 (en) | 1997-12-10 | 2009-08-04 | Sierra Molecular Corp. | Removal of molecular assay interferences |
| DK2314315T3 (en) | 1999-06-01 | 2015-02-02 | Biogen Idec Inc | Blocking monoclonal antibody to the human alpha1-I domain of VLA-1 and their use for the treatment of inflammatory diseases |
| NZ529494A (en) | 2001-04-13 | 2005-08-26 | Biogen Idec Inc | Antibodies to VLA-1 |
| US8877901B2 (en) | 2002-12-13 | 2014-11-04 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
| US7591994B2 (en) | 2002-12-13 | 2009-09-22 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
| US20160279239A1 (en) | 2011-05-02 | 2016-09-29 | Immunomedics, Inc. | Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease |
| CA2494310A1 (en) * | 2002-08-01 | 2004-02-12 | Immunomedics, Inc. | Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof |
| US8193318B2 (en) * | 2002-08-14 | 2012-06-05 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
| US8946387B2 (en) | 2002-08-14 | 2015-02-03 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
| US8044180B2 (en) * | 2002-08-14 | 2011-10-25 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
| US20060034845A1 (en) | 2002-11-08 | 2006-02-16 | Karen Silence | Single domain antibodies directed against tumor necrosis factor alpha and uses therefor |
| US9320792B2 (en) | 2002-11-08 | 2016-04-26 | Ablynx N.V. | Pulmonary administration of immunoglobulin single variable domains and constructs thereof |
| NZ540194A (en) * | 2002-11-08 | 2008-07-31 | Ablynx Nv | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| PT2316852E (pt) * | 2002-11-08 | 2014-06-23 | Ablynx Nv | Anticorpos de domínio único estáveis |
| EP1558650A2 (en) * | 2002-11-08 | 2005-08-03 | Ablynx N.V. | Camelidae antibodies against immunoglobulin e and use thereof for the treatment of allergic disorders |
| US20100003253A1 (en) * | 2002-11-08 | 2010-01-07 | Ablynx N.V. | Single domain antibodies directed against epidermal growth factor receptor and uses therefor |
| US7960512B2 (en) * | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| JP2006524039A (ja) | 2003-01-09 | 2006-10-26 | マクロジェニクス，インコーポレーテッド | 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法 |
| JP2007535895A (ja) * | 2003-05-01 | 2007-12-13 | イムクローン システムズ インコーポレイティド | ヒトインシュリン様成長因子−１受容体に対する完全ヒト抗体 |
| US7172751B2 (en) * | 2003-06-13 | 2007-02-06 | Immunomedics, Inc. | D-amino acid peptides |
| EP2251357A1 (en) * | 2003-11-07 | 2010-11-17 | Ablynx N.V. | Camelidae single domain antibodies VHH directed against epidermal growth factor receptor and uses therefor |
| WO2005080586A1 (en) * | 2004-02-13 | 2005-09-01 | Immunomedics, Inc. | Fusion proteins containing recombinant cytotoxic rnases |
| WO2005097832A2 (en) * | 2004-03-31 | 2005-10-20 | Genentech, Inc. | Humanized anti-tgf-beta antibodies |
| US20050227289A1 (en) * | 2004-04-09 | 2005-10-13 | Reilly Edward B | Antibodies to erythropoietin receptor and uses thereof |
| US7521542B2 (en) | 2004-05-10 | 2009-04-21 | Macrogenics, Inc. | Humanized FcγRIIB-specific antibodies and methods of use thereof |
| US7632497B2 (en) * | 2004-11-10 | 2009-12-15 | Macrogenics, Inc. | Engineering Fc Antibody regions to confer effector function |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| JP2006248978A (ja) | 2005-03-10 | 2006-09-21 | Mebiopharm Co Ltd | 新規なリポソーム製剤 |
| CN101612399B (zh) * | 2005-06-17 | 2013-11-27 | 英克隆有限责任公司 | 用作治疗继发性骨肿瘤的抗PDGFRα抗体 |
| PL1919503T3 (pl) | 2005-08-10 | 2015-04-30 | Macrogenics Inc | Identyfikacja i inżynieria przeciwciał ze zmiennymi regionami FC oraz sposoby ich stosowania |
| CN101484587B (zh) * | 2006-02-03 | 2014-02-12 | 英克隆有限责任公司 | Igf-ir拮抗剂作为辅药用于前列腺癌的治疗 |
| CA2644903A1 (en) * | 2006-03-10 | 2007-09-20 | Macrogenics, Inc. | Identification and engineering of antibodies with variant heavy chains and methods of using same |
| EP2839843B1 (en) * | 2006-05-25 | 2018-06-20 | Biogen MA Inc. | VLA-1 antagonist for use in treating stroke |
| ES2489646T3 (es) | 2006-05-26 | 2014-09-02 | Macrogenics, Inc. | Anticuerpos humanizados específicos a Fc gamma RIIB y sus métodos de uso |
| WO2008002933A2 (en) | 2006-06-26 | 2008-01-03 | Macrogenics, Inc. | Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof |
| PT2029173T (pt) | 2006-06-26 | 2016-11-02 | Macrogenics Inc | Anticorpos específicos fc rib e seus métodos de uso |
| US20080112961A1 (en) * | 2006-10-09 | 2008-05-15 | Macrogenics, Inc. | Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same |
| US8652466B2 (en) * | 2006-12-08 | 2014-02-18 | Macrogenics, Inc. | Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting |
| WO2009151717A2 (en) | 2008-04-02 | 2009-12-17 | Macrogenics, Inc. | Bcr-complex-specific antibodies and methods of using same |
| WO2009000099A2 (en) | 2007-06-25 | 2008-12-31 | Esbatech Ag | Methods of modifying antibodies, and modified antibodies with improved functional properties |
| PT2247304T (pt) | 2008-04-02 | 2016-08-29 | Macrogenics Inc | Anticorpos especificos de her2/neu e métodos de utilização dos mesmos |
| CA2739663A1 (en) * | 2008-10-10 | 2010-05-15 | Anaphore, Inc. | Polypeptides that bind trail-r1 and trail-r2 |
| KR101593285B1 (ko) | 2008-10-29 | 2016-02-11 | 아블린쓰 엔.브이. | 단일 도메인 항원 결합 분자의 제형 |
| WO2010056550A1 (en) * | 2008-10-29 | 2010-05-20 | Wyeth Llc | Methods for purification of single domain antigen binding molecules |
| EP3903829B1 (en) | 2009-02-13 | 2023-05-03 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
| AU2010288469A1 (en) * | 2009-08-31 | 2012-03-01 | Roche Glycart Ag | Affinity-matured humanized anti CEA monoclonal antibodies |
| EP2478110B1 (en) | 2009-09-16 | 2016-01-06 | Immunomedics, Inc. | Class i anti-cea antibodies and uses thereof |
| TR201804897T4 (tr) | 2009-10-07 | 2018-06-21 | Macrogenics Inc | Fukosi̇lasyon ölçüsünün deği̇şi̇mleri̇nden dolayi geli̇şmi̇ş efektör i̇şlevi̇ sergi̇leyen fc bölgesi̇ni̇ i̇çeren poli̇pepti̇tler ve bunlarin kullanimlarina yöneli̇k yöntemler |
| US20110086806A1 (en) * | 2009-10-09 | 2011-04-14 | Anaphore, Inc. | Polypeptides that Bind IL-23R |
| ES2978177T3 (es) | 2009-12-02 | 2024-09-06 | Immunomedics Inc | Combinación de radio inmunoterapia y conjugados anticuerpo-fármaco para mejorar la terapia contra el cáncer |
| SG10201604336VA (en) | 2010-03-04 | 2016-07-28 | Macrogenics Inc | Antibodies Reactive With B7-H3, Immunologically Active Fragments Thereof And Uses Thereof |
| PH12012501751A1 (en) | 2010-03-04 | 2012-11-12 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| FR2960974B1 (fr) | 2010-06-03 | 2016-12-30 | Biosynex | Procede de detection de rupture de membranes |
| EP2632490A4 (en) * | 2010-10-29 | 2014-10-22 | Immunogen Inc | NOVEL MOLECULES BINDING TO THE EGF RECEPTOR AND IMMUNOCONJUGATES THEREOF |
| CA2831572C (en) | 2011-05-02 | 2019-11-26 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
| SG11201403062YA (en) | 2011-12-13 | 2014-07-30 | Engeneic Molecular Delivery Pty Ltd | Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors |
| CN103215255B (zh) * | 2012-01-19 | 2015-06-17 | 深圳华大基因科技有限公司 | 用于扩增免疫球蛋白轻链cdr3序列的引物集及其用途 |
| WO2013123114A2 (en) | 2012-02-16 | 2013-08-22 | Santarus, Inc. | Antibody formulations |
| AU2013302696B9 (en) | 2012-08-14 | 2018-08-09 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
| DK2900277T3 (da) | 2012-12-13 | 2022-04-04 | Immunomedics Inc | Doser af immunokonjugater af antistoffer og sn-38 til forbedret effektivitet og reduceret toksicitet |
| US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
| EP2774930A1 (en) | 2013-03-07 | 2014-09-10 | Aptenia S.R.L. | Metallocene compounds and labeled molecules comprising the same for in vivo imaging. |
| EP2972230B1 (en) | 2013-03-15 | 2021-07-21 | Hycor Biomedical LLC | Device and associated method for performing luminescence and fluorescence measurements of a sample |
| WO2015126548A1 (en) | 2014-02-21 | 2015-08-27 | Ibc Pharmaceuticals, Inc. | Disease therapy by inducing immune response to trop-2 expressing cells |
| CA2935748A1 (en) | 2014-02-25 | 2015-09-03 | Immunomedics, Inc. | Humanized rfb4 anti-cd22 antibody |
| HUE042829T2 (hu) | 2014-04-03 | 2019-07-29 | Igm Biosciences Inc | Módosított J-lánc |
| WO2015200260A1 (en) | 2014-06-24 | 2015-12-30 | Immunomedics, Inc. | Anti-histone therapy for vascular necrosis in severe glomerulonephritis |
| JP7080055B2 (ja) | 2014-09-08 | 2022-06-03 | ルタナ ゲーエムベーハー | 細胞の細胞質への分子の送達のための構築物 |
| JP6678941B2 (ja) | 2014-10-07 | 2020-04-15 | イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． | 抗体−薬物コンジュゲートのネオアジュバント使用 |
| RU2021124437A (ru) | 2015-04-03 | 2021-09-29 | Еурека Терапьютикс, Инк. | Конструкции, направленные на комплексы пептида afp/mhc, и виды их использования |
| JP6746845B2 (ja) | 2015-04-22 | 2020-08-26 | イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． | 循環ｔｒｏｐ−２陽性癌細胞の単離、検出、診断及び／または特徴付け |
| WO2016210108A1 (en) | 2015-06-25 | 2016-12-29 | Immunomedics, Inc. | Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
| PL3316885T3 (pl) | 2015-07-01 | 2021-12-06 | Immunomedics, Inc. | Immunokoniugaty przeciwciało-sn-38 z linkerem cl2a |
| AU2016329197B2 (en) | 2015-09-30 | 2021-01-21 | Igm Biosciences, Inc. | Binding molecules with modified J-chain |
| CN108463472A (zh) | 2015-09-30 | 2018-08-28 | Igm生物科学有限公司 | 具有修饰的j-链的结合分子 |
| CN106810609A (zh) * | 2015-11-27 | 2017-06-09 | 苏州君盟生物医药科技有限公司 | 抗pcsk9抗体及其应用 |
| US10961311B2 (en) | 2016-04-15 | 2021-03-30 | Macrogenics, Inc. | B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof |
| EP3606964A4 (en) | 2017-04-03 | 2020-12-09 | Immunomedics, Inc. | SUBCUTANE ADMINISTRATION OF ANTIBODY DRUG CONJUGATES FOR CANCER THERAPY |
| CN111295394B (zh) | 2017-08-11 | 2024-06-11 | 豪夫迈·罗氏有限公司 | 抗cd8抗体及其用途 |
| US20210338834A1 (en) | 2018-09-26 | 2021-11-04 | Ascendis Pharma A/S | Degradable hyaluronic acid hydrogels |
| CN110865416A (zh) * | 2019-11-15 | 2020-03-06 | 南华大学 | 一种放射性胁迫下的植物生化指征测量方法 |
| US20230256114A1 (en) | 2020-07-07 | 2023-08-17 | Bionecure Therapeutics, Inc. | Novel maytansinoids as adc payloads and their use for the treatment of cancer |
| WO2022008699A1 (en) | 2020-07-09 | 2022-01-13 | F. Hoffmann-La Roche Ag | Concentrated compositions of proteins, their preparation and use thereof |
| US20250073349A1 (en) | 2021-05-10 | 2025-03-06 | Kawasaki Institute Of Industrial Promotion | Antibody having reduced binding affinity for antigen |
| CN113416729B (zh) * | 2021-05-18 | 2022-11-22 | 遵义医科大学附属医院 | 一种肝脏靶向调控甲胎蛋白基因的shRNA和cDNA及其应用 |
| CN117460744A (zh) * | 2021-05-31 | 2024-01-26 | 南京传奇生物科技有限公司 | 靶向afp肽/mhc复合物的抗体及其用途 |
| CN118043080A (zh) | 2021-08-13 | 2024-05-14 | 昆山新蕴达生物科技有限公司 | 一种基于微管抑制剂的抗体偶联药物 |
| CN116120455B (zh) * | 2021-08-23 | 2023-11-07 | 东莞市朋志生物科技有限公司 | 一种抗ca15-3蛋白的重组抗体 |
| JP2024532295A (ja) | 2021-08-24 | 2024-09-05 | クンシャン シンユンター バイオテック カンパニー，リミティド | 切断可能なリンカーを介して結合した抗体薬物複合体 |
| EP4445919A1 (en) | 2021-12-09 | 2024-10-16 | Kunshan Xinyunda Biotech Co., Ltd. | Antibody-drug conjugate having improved affinity, and preparation method therefor and application thereof |
| EP4570272A1 (en) | 2022-08-10 | 2025-06-18 | Kowa Company, Ltd. | New drug complex |
| TW202506733A (zh) | 2023-06-12 | 2025-02-16 | 美商安進公司 | 淋巴毒素β受體促效劑結合蛋白 |
| WO2024263821A2 (en) * | 2023-06-20 | 2024-12-26 | The Methodist Hospital | Antigen-specific t cell receptors and chimeric antigen receptors, and methods of use in immune signaling modulation for cancer immunotherapy |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3972902A (en) * | 1971-01-20 | 1976-08-03 | General Electric Company | 4,4'-Isopropylidene-bis(3- and 4-phenyleneoxyphthalic anhydride) |
| US3847867A (en) * | 1971-01-20 | 1974-11-12 | Gen Electric | Polyetherimides |
| US3814869A (en) * | 1971-10-13 | 1974-06-04 | Porta Systems Corp | Outgoing trunk extender test and monitor apparatus for central telephone equipment |
| US3803085A (en) * | 1972-12-29 | 1974-04-09 | Gen Electric | Method for making polyetherimides |
| US3905942A (en) * | 1973-06-22 | 1975-09-16 | Gen Electric | Method for making polyetherimides and products produced thereby |
| US3850885A (en) * | 1973-11-23 | 1974-11-26 | Gen Electric | Method for making polyetherimides |
| US3855178A (en) * | 1973-12-03 | 1974-12-17 | Gen Electric | Method for making polyetherimides |
| US3852242A (en) * | 1973-12-03 | 1974-12-03 | Gen Electric | Method for making polyetherimide |
| US3983093A (en) * | 1975-05-19 | 1976-09-28 | General Electric Company | Novel polyetherimides |
| US4036945A (en) * | 1976-05-03 | 1977-07-19 | The Massachusetts General Hospital | Composition and method for determining the size and location of myocardial infarcts |
| US4331647A (en) * | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4455410A (en) * | 1982-03-18 | 1984-06-19 | General Electric Company | Polyetherimide-polysulfide blends |
| US4443591A (en) * | 1983-01-21 | 1984-04-17 | General Electric Company | Method for making polyetherimide |
| US5011771A (en) * | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
| GR850899B (enExample) * | 1984-04-12 | 1985-11-25 | Gen Hospital Corp | |
| US4824659A (en) * | 1985-06-07 | 1989-04-25 | Immunomedics, Inc. | Antibody conjugates |
| US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
| US5057313A (en) * | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
| US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4704692A (en) * | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US5567610A (en) * | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US5612016A (en) * | 1988-04-01 | 1997-03-18 | Immunomedics, Inc. | Conjugates of antibodies and bifunctional ligands |
| JPH0390037A (ja) * | 1989-08-31 | 1991-04-16 | Denki Kagaku Kogyo Kk | リポソーム製剤 |
| US5229275A (en) * | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5633425A (en) * | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| EP0643583B1 (en) | 1992-05-06 | 2000-07-26 | Immunomedics, Inc. | Intraoperative, intravascular and endoscopic tumor and lesion detection and therapy |
| US6096289A (en) | 1992-05-06 | 2000-08-01 | Immunomedics, Inc. | Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy |
| US5443953A (en) * | 1993-12-08 | 1995-08-22 | Immunomedics, Inc. | Preparation and use of immunoconjugates |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US7166295B1 (en) * | 1995-05-26 | 2007-01-23 | Meir Strahilevitz | Methods of treatment and diagnostic visualization, particularly in cancer |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| US5753206A (en) | 1995-06-07 | 1998-05-19 | Immunomedics, Inc. | Radiometal-binding analogues of luteinizing hormone releasing hormone |
| WO1997034632A1 (en) | 1996-03-20 | 1997-09-25 | Immunomedics, Inc. | Glycosylated humanized b-cell specific antibodies |
| DE69737867T2 (de) | 1996-05-03 | 2007-10-18 | Immunomedics, Inc. | Zielgerichtete kombinations-immuntherapie für krebs |
| US20020032315A1 (en) * | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| JP2002530081A (ja) | 1998-11-18 | 2002-09-17 | ジェネンテック・インコーポレーテッド | 親抗体より高度な結合親和性を持つ抗体変異体 |
| ATE361469T1 (de) * | 1998-12-01 | 2007-05-15 | Phylonix Pharmaceuticals Inc | Methoden zur introduktion heterologer zellen in fische |
| JP2002543044A (ja) * | 1999-03-01 | 2002-12-17 | ジェネンテック・インコーポレーテッド | 癌の治療及び診断のための抗体 |
| CA2370477C (en) | 1999-04-15 | 2010-06-29 | Crucell Holland B.V. | Recombinant protein production in a human cell using sequences encoding adenovirus e1 protein |
| PL203326B1 (pl) * | 1999-06-25 | 2009-09-30 | Genentech Inc | Przeciwciało, kompozycja farmaceutyczna, koniugat, izolowany kwas nukleinowy, wektor, komórka gospodarza i sposób wytwarzania przeciwciała |
| US20020048550A1 (en) | 2000-07-20 | 2002-04-25 | Vallera Daniel A. | Radiolabeled immunotoxins |
| CA2494310A1 (en) * | 2002-08-01 | 2004-02-12 | Immunomedics, Inc. | Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof |
-
2003
- 2003-08-01 CA CA002494310A patent/CA2494310A1/en not_active Abandoned
- 2003-08-01 EP EP03766456A patent/EP1546203B1/en not_active Expired - Lifetime
- 2003-08-01 US US10/631,722 patent/US7300655B2/en not_active Expired - Lifetime
- 2003-08-01 JP JP2004525545A patent/JP5138867B2/ja not_active Expired - Fee Related
- 2003-08-01 WO PCT/GB2003/003325 patent/WO2004013180A2/en not_active Ceased
- 2003-08-01 AU AU2003248982A patent/AU2003248982B2/en not_active Ceased
- 2003-08-01 KR KR1020057001867A patent/KR101115797B1/ko not_active Expired - Fee Related
-
2005
- 2005-02-01 IL IL166632A patent/IL166632A/en unknown
-
2007
- 2007-10-11 US US11/870,627 patent/US7501498B2/en not_active Expired - Fee Related
-
2009
- 2009-01-26 US US12/359,745 patent/US8017736B2/en not_active Expired - Fee Related
-
2010
- 2010-02-19 AU AU2010200646A patent/AU2010200646B2/en not_active Ceased
- 2010-03-26 JP JP2010073011A patent/JP5161254B2/ja not_active Expired - Fee Related
-
2011
- 2011-04-20 US US13/090,391 patent/US8084029B2/en not_active Expired - Fee Related
- 2011-11-22 US US13/302,565 patent/US8268312B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006516086A5 (enExample) | ||
| JP2006507803A5 (enExample) | ||
| JP2006513695A5 (enExample) | ||
| JP5138867B2 (ja) | α−フェトタンパク質Ｉｍｍｕ３１抗体および融合タンパク質ならびにその使用方法 | |
| JP4538062B2 (ja) | 二重特異性抗体とともに使用される新規なペプチド型薬剤の製造および使用 | |
| US7387772B1 (en) | Chimeric, human and humanized anti-CSAP monoclonal antibodies | |
| JP2024150445A5 (enExample) | ||
| JP2006502698A5 (enExample) | ||
| RU2005100777A (ru) | Моноклональное антитело рам4 и его применение для диагностики и лечения рака поджелудочной железы | |
| JP2006521286A5 (enExample) | ||
| JP7279761B2 (ja) | 卵巣癌の検出および治療のための組成物および方法 | |
| JP2009531324A5 (enExample) | ||
| JPWO2019165077A5 (enExample) | ||
| JPWO2022031710A5 (enExample) | ||
| AU2024247883A1 (en) | Methods of treating melanoma using an anti-ctla4 antibody | |
| WO2025088085A1 (en) | Image guided biopsy of her2 positive lesions | |
| RU2020129339A (ru) | Антитела с двойной специфичностью |